SAB Biotherapeutics

SABS (NasdaqCM)

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing human polyclonal immunotherapeutic antibodies for immune system disorders and infectious diseases in the United States. Its lead candidate, SAB-142, is a potentially disease-modifying, redosable immunotherapy for autoimmune type 1 diabetes in Phase 2b trials. Founded in 2014 and headquartered in Miami Beach, Florida.